Enzalutamide (Xtandi) for Metastatic Castration Sensitive Prostate Cancer - Details


( Last Updated : October 8, 2020)
Generic Name:
Enzalutamide
Project Status:
Complete
Therapeutic Area:
mHSPC
Manufacturer:
Astellas Pharma Canada, Inc.
Brand Name:
Xtandi
Project Line:
Reimbursement Review
Project Number:
PC0209-000
NOC Date:

Details


Strength:
40mg
Tumour Type:
Genitourinary
Indications:
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Funding Request:
For the treatment of patients with metastatic castration sensitive prostate cancer
Pre Noc Submission:
Yes
Sponsor:
Astellas Pharma Canada, Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Funding Request:
For the treatment of patients with metastatic castration sensitive prostate cancer
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.